- DMTK’s SmartSticker solution is proprietary and has been shown to be more effective and accurate than traditional biopsy-based diagnostic approaches, but the company must further commercialize this offering.
- DMTK has made significant sales, marketing and infrastructure investments over the past 6 months, which should drive 2022 to be a record financial year for the company.
- Investors should approach this opportunity with caution while collecting more data on DMTK’s ability to grow sales. The longer-term opportunity remains if DMTK can execute on its core growth strategies.
For further details see:
DermTech - Taking A Second Look At The Growth Thesis